12/14/2010
Helm AG Aquires Shares in Amarin Technologies S.A.
Hamburg, December 10th, 2010
Effective September 28th, 2010, Hamburg based HELM AG has purchased a 30% shareholding in Amarin Technologies S.A. a privately owned pharmaceutical development company in Buenos Aires, Argentina.
Amarin has more than 20 years of experience in the technology of transdermal delivery systems and owns several patents. The mid-size company has been cooperating with HELM successfully on the development of a pain release patch.
Both Sergio Lucero, CEO of Amarin, and Dieter Schnabel, CEO of HELM, are convinced that HELM, with its marketing strength in more than 32 countries is a perfect fit for Amarin’s expertise in transdermal technology. “We are confident that this strategic step will be very beneficial to both companies.”
The participation gives HELM’s pharmaceutical division direct access to various generic transdermal products, presently still a niche market but with strong growth potential. It will further strengthen the company’s position within the global pharmaceutical market. At the same time, it increases Amarin’s access to international markets.
For more information from HELM AG, please contact: Annegret Dehning – Executive Manager Admin./Public Relations, Tel. +49 4023751820, e-mail: A.Dehning@helmag.com For more information from Amarin Technologies SA, please contact Ms. Emilce Diaz, Tel +54 11 5921 6387, e-mail: emilce.diaz@amarintech.com.ar
[+]
|
|
|
8/5/2009
Fentanyl TDS New Markets
Amarin Technologies S.A. is proud to announce that Fentanyl TDS is being exported to Taiwan (as Fentanyl HPQ, for Bio-Pro), since March 2009, and France (as Fentanyl Biogaran, for Biogaran), since
[+]
|
|
|
